Brain imaging in migraine research

Headache

Volumn 50, Issue 9, 2010, Pages 1523-1527

  Borsook, David ^a   Hargreaves, Richard ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; TRIPTAN DERIVATIVE;

BEHAVIOR THERAPY; DISEASE PREDISPOSITION; DRUG TOLERABILITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HOSPITAL; HUMAN; LABORATORY; MIGRAINE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVATIONAL STUDY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TREATMENT RESPONSE;

ANALGESICS; BIOMEDICAL RESEARCH; BRAIN; DIAGNOSTIC IMAGING; HUMANS; MIGRAINE DISORDERS; NEUROPHARMACOLOGY;

EID: 77957738938     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01761.x     Document Type: Review

References (32)

1. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987 27 : 416 420.
2. Bigal ME, Lipton RB. Clinical course in migraine: Conceptualizing migraine transformation. Neurology. 2008 71 : 848 855.
3. Bigal M. Migraine chronification - concept and risk factors. Discov Med. 2009 8 : 145 150.
4. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001 41 : 629 637.
5. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 1 : 658 660.
6. Moulton E, Burstein R, Pendse G, Hargreaves R, Becerra L, Borsook D. Comparison of Cortical Responses to Noxious Contact Heat Using fMRI in Interictal Migraine Patients and Matched Healthy Controls. San Francisco, CA : Human Brain Mapping 2009.
7. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001 98 : 4687 4692.
8. Vingen JV, Pareja JA, Storen O, White LR, Stovner LJ. Phonophobia in migraine. Cephalalgia. 1998 18 : 243 249.
9. Demarquay G, Royet JP, Mick G, Ryvlin P. Olfactory hypersensitivity in migraineurs: A H(2)(15)O-PET study. Cephalalgia. 2008 28 : 1069 1080.
10. Ruiz L, Ferrandi D. Topiramate in migraine progression. J Headache Pain. 2009 10 : 419 422.
11. Aurora SK. Spectrum of illness: Understanding biological patterns and relationships in chronic migraine. Neurology. 2009 72 : S8 13.
12. De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: Potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009 29 : 1277 1284.
13. Biondi DM. Opioid resistance in chronic daily headache: A synthesis of ideas from the bench and bedside. Curr Pain Headache Rep. 2003 7 : 67 75.
14. May A, Matharu M. New insights into migraine: Application of functional and structural imaging. Curr Opin Neurol. 2007 20 : 306 309.
15. DaSilva AF, Granziera C, Snyder J, Hadjikhani N. Thickening in the somatosensory cortex of patients with migraine. Neurology. 2007 69 : 1990 1995.
16. Rodriguez-Raecke R, Niemeier A, Ihle K, Ruether W, May A. Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. J Neurosci. 2009 29 : 13746 13750.
17. Wang SJ, Lirng JF, Fuh JL, Chen JJ. Reduction in hypothalamic 1H-MRS metabolite ratios in patients with cluster headache. J Neurol Neurosurg Psychiatry. 2006 77 : 622 625.
18. Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC. Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia. 1995 15 : 489 493.
19. Prescot A, Becerra L, Pendse G, et al. Excitatory neurotransmitters in brain regions in interictal migraine patients. Mol Pain. 2009 5 : 34.
20. Borras MC, Becerra L, Ploghaus A, et al. fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol. 2004 91 : 2723 2733.
21. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg. 2006 103 : 208 216, table of contents.
22. Macedo A, Banos JE, Farre M. Placebo response in the prophylaxis of migraine: A meta-analysis. Eur J Pain. 2008 12 : 68 75.
23. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 350 : 1104 1110.
24. Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: Unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007 28 : 580 587.
25. Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine: Is this a new era? Neurology. 2008 70 : 1300 1301.
26. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 372 : 2115 2123.
27. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol. 2006 95 : 1298 1306.
28. Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci. 2005 25 : 5877 5883.
29. Marvizon JC, Perez OA, Song B, et al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: Localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience. 2007 148 : 250 265.
30. Upadhyay J, Nutile L, Anderson J, et al. Potential Use of Phmri to Reflect Target Engagement: PET Equivalent? Chicago, IL : Society for Neuroscience 2009.
31. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov. 2006 5 : 411 424.
32. Sur C, Hargreaves R, Bell I, et al. Binding Pattern of Novel CGRP Receptor Antagonists in Rhesus Monkey and Human Central Nervous System: Towards the Development of a PET Trace. Philadelphia, PA : International Headache Congress 2009.